Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
The MaxCyte STX Scalable Transfection Presented at LabAutomation 2009
January 26, 2009
Gaithersburg, Maryland - MaxCyteInc., MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces the presentation of the MaxCyte® STX™ Scalable Transfection System at LabAutomation 2009 in the Rapid Fire Innovation Session in Palm Springs, CA. “The selection of the MaxCyte STX for this session attests to the uniqueness of MaxCyte’s large scale transfection technology. Using the MaxCyte STX, more than ten billion cells can be transfected in less than 30 minutes with one or more loading agents at efficiencies and cell viabilities often exceeding 90%. The speed, scale, and flexibility of our technology allow the development of an expanded range of relevant cell-based assays for drug discovery” says Dr. Karen Donato, Vice President of Sales and Marketing.